Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETER PAIN: Naltrexone and Nalmefene for Pain in HIV+ Heavy Drinkers
NCT03278886Phase 2Completed
- Sponsor
- Boston Medical Center
- Start
- Jul 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of naltrexone and nalmefene in chronic pain, sponsored by Boston Medical Center. Primary endpoint: Medication Tolerability Measured Via a 0-100 Visual Analog Scale at 8 weeks. Started Jul 2018; status: completed.
02
Drugs
naltrexonenalmefene
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT03278886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278886.